JP2020505402A5 - - Google Patents

Download PDF

Info

Publication number
JP2020505402A5
JP2020505402A5 JP2019540361A JP2019540361A JP2020505402A5 JP 2020505402 A5 JP2020505402 A5 JP 2020505402A5 JP 2019540361 A JP2019540361 A JP 2019540361A JP 2019540361 A JP2019540361 A JP 2019540361A JP 2020505402 A5 JP2020505402 A5 JP 2020505402A5
Authority
JP
Japan
Prior art keywords
group
alkyl
optionally
heterocyclyl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019540361A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020505402A (ja
JP7050791B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2018/051387 external-priority patent/WO2018138029A1/en
Publication of JP2020505402A publication Critical patent/JP2020505402A/ja
Publication of JP2020505402A5 publication Critical patent/JP2020505402A5/ja
Application granted granted Critical
Publication of JP7050791B2 publication Critical patent/JP7050791B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019540361A 2017-01-26 2018-01-22 ベンジルオキシピリジルシクロプロパンカルボン酸、その医薬組成物及び使用 Active JP7050791B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17153388 2017-01-26
EP17153388.8 2017-01-26
PCT/EP2018/051387 WO2018138029A1 (en) 2017-01-26 2018-01-22 Benzyloxypyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof

Publications (3)

Publication Number Publication Date
JP2020505402A JP2020505402A (ja) 2020-02-20
JP2020505402A5 true JP2020505402A5 (enExample) 2021-01-14
JP7050791B2 JP7050791B2 (ja) 2022-04-08

Family

ID=57906578

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019540361A Active JP7050791B2 (ja) 2017-01-26 2018-01-22 ベンジルオキシピリジルシクロプロパンカルボン酸、その医薬組成物及び使用

Country Status (5)

Country Link
US (1) US10913720B2 (enExample)
EP (1) EP3573953A1 (enExample)
JP (1) JP7050791B2 (enExample)
CN (1) CN110198928B (enExample)
WO (1) WO2018138029A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110312714B (zh) * 2017-01-26 2022-12-09 勃林格殷格翰国际有限公司 苄基氧基吡嗪基环丙烷甲酸、其药物组合物和用途
JP7050791B2 (ja) 2017-01-26 2022-04-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンジルオキシピリジルシクロプロパンカルボン酸、その医薬組成物及び使用
US10253004B2 (en) * 2017-01-26 2019-04-09 Boehringer Ingelheim International Gmbh Indanylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
JP7023969B2 (ja) 2017-01-26 2022-02-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンジルアミノピリジルシクロプロパンカルボン酸、その医薬組成物及び使用
CN110248929B (zh) 2017-01-26 2023-05-12 勃林格殷格翰国际有限公司 苄基氨基吡嗪基环丙烷甲酸、其药物组合物和用途
EP3580222B1 (en) 2017-02-08 2021-04-07 Boehringer Ingelheim International GmbH Indanylaminoazadihydrobenzofuranylacetic acids, pharmaceutical compositions for the treatment of diabetes
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
KR102708681B1 (ko) 2018-02-13 2024-09-26 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
EP4600247A3 (en) 2018-04-19 2025-11-19 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
UA126421C2 (uk) 2018-07-13 2022-09-28 Гіліад Сайєнсіз, Інк. Інгібітори pd-1/pd-l1
US11236085B2 (en) 2018-10-24 2022-02-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
BR112022006546A2 (pt) 2019-10-07 2022-08-30 Kallyope Inc Agonistas de gpr119
CA3173731A1 (en) 2020-02-28 2021-09-02 Kallyope, Inc. Gpr40 agonists
CN116323608A (zh) 2020-05-19 2023-06-23 卡尔优普公司 Ampk活化剂
EP4172162A4 (en) 2020-06-26 2024-08-07 Kallyope, Inc. AMPK ACTIVATORS

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US628476A (en) 1898-03-18 1899-07-11 Joseph Howard Kirk Junction of cycle, motor-car, or other frames, &c.
US2505322A (en) 1945-09-14 1950-04-25 Gibson Refrigerator Co Refrigerator cabinet
US2560111A (en) 1946-11-07 1951-07-10 Raymond T Levine Buffing chuck
US2656003A (en) 1948-02-27 1953-10-20 Inst Of Inventive Res High explosive disk-shaped charge for seismic exploration
US2727340A (en) 1953-08-31 1955-12-20 Alfred S Zanotta Portable tool for reconditioning crane rails
US5356287A (en) 1987-03-16 1994-10-18 Mcintyre Kevin M Simulating presence
EP1559422B1 (en) 2002-11-08 2014-04-30 Takeda Pharmaceutical Company Limited Receptor function controlling agent
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
EP1630152A4 (en) 2003-05-30 2009-09-23 Takeda Pharmaceutical CONDENSED CYCLIC COMPOUND
WO2005051890A1 (en) 2003-11-19 2005-06-09 Smithkline Beecham Corporation Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40
WO2005087710A1 (ja) 2004-03-15 2005-09-22 Takeda Pharmaceutical Company Limited アミノフェニルプロパン酸誘導体
DE102004017930A1 (de) 2004-04-14 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
JP2008530162A (ja) 2005-02-15 2008-08-07 グラクソ グループ リミテッド グルタミン酸受容体を増強する化合物および医薬におけるそれらの使用
CA2602566A1 (en) 2005-03-28 2006-10-05 Pfizer Inc. Substituted aryloxoethyl cyclopropanecarboxamide compounds as vr1 receptor antagonists
US7664629B2 (en) 2005-07-19 2010-02-16 Xerox Corporation Second language writing advisor
EP1916234B1 (en) * 2005-07-29 2014-11-12 Takeda Pharmaceutical Company Limited Cyclopropanecarboxylic acid compound
EP1924546A1 (en) 2005-09-14 2008-05-28 Amgen, Inc Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
US20090036473A1 (en) 2006-03-15 2009-02-05 William Dalby Brown Novel quinazolinone derivatives and their medical use
KR20080103584A (ko) 2006-03-30 2008-11-27 아사히 가세이 파마 가부시키가이샤 치환 이환식 환상 유도체 및 그 용도
CL2007001873A1 (es) 2006-06-27 2008-01-04 Takeda Pharmaceutical Acido((3s))-6-((¨2,6-dimetil-4-(3-(metilsulfonil)-propoxi)bifenil-3-il)metoxi-2,3-dihidro-1-benzofuran-3-il)acetico o una sal del mismo
TW200838526A (en) 2006-12-01 2008-10-01 Astellas Pharma Inc Carboxylic acid derivatives
CA2727340A1 (en) 2008-06-25 2009-12-30 Daiichi Sankyo Company, Limited Carboxylic acid compound
ES2345916B1 (es) 2008-10-14 2011-09-14 Clipdorfix, S.L. Dispositivo de fijacion liberable de elementos adosados.
US8748462B2 (en) 2008-10-15 2014-06-10 Amgen Inc. Spirocyclic GPR40 modulators
US20110269783A1 (en) 2008-11-10 2011-11-03 Neurosearch A/S Novel 2,3-diamino-quinazolinone derivatives and their medical use
JP2012136438A (ja) 2009-04-22 2012-07-19 Astellas Pharma Inc テトラゾール化合物
WO2010143733A1 (en) 2009-06-09 2010-12-16 Takeda Pharmaceutical Company Limited Novel fused cyclic compound and use thereof
WO2011094890A1 (en) 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
TW201643169A (zh) 2010-07-09 2016-12-16 艾伯維股份有限公司 作為s1p調節劑的螺-哌啶衍生物
EP2646425B1 (en) 2010-12-01 2015-06-10 Boehringer Ingelheim International Gmbh Indanyloxydihydrobenzofuranylacetic acids useful for the treatment of metabolic syndrome
US8642585B2 (en) 2012-03-26 2014-02-04 Boehringer Ingelheim International Gmbh Indanyloxydihydrobenzofuranylacetic acids
US8633182B2 (en) 2012-05-30 2014-01-21 Boehringer Ingelheim International Gmbh Indanyloxyphenylcyclopropanecarboxylic acids
WO2014019186A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
HK1210144A1 (en) 2012-11-28 2016-04-15 勃林格殷格翰国际有限公司 New indanyloxydihydrobenzofuranylacetic acids
US20140163025A1 (en) 2012-12-07 2014-06-12 Boehringer Ingelheim International Gmbh Indanyloxydihydrobenzofuranylacetic acids
KR101735787B1 (ko) 2013-02-28 2017-05-16 주식회사 티움바이오 삼환식 화합물 및 이의 용도
EP3036237A4 (en) 2013-08-23 2017-01-25 Fujian Haixi Pharmaceuticals Co. Ltd Carboxylic acid compounds in treatment of diabetes mellitus
JP7050797B2 (ja) * 2016-10-25 2022-04-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンジルアミノピリジルシクロプロパンカルボン酸、その医薬組成物および使用
US10253004B2 (en) 2017-01-26 2019-04-09 Boehringer Ingelheim International Gmbh Indanylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
CN110248929B (zh) 2017-01-26 2023-05-12 勃林格殷格翰国际有限公司 苄基氨基吡嗪基环丙烷甲酸、其药物组合物和用途
CN110312714B (zh) 2017-01-26 2022-12-09 勃林格殷格翰国际有限公司 苄基氧基吡嗪基环丙烷甲酸、其药物组合物和用途
JP7023969B2 (ja) 2017-01-26 2022-02-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンジルアミノピリジルシクロプロパンカルボン酸、その医薬組成物及び使用
JP7050791B2 (ja) 2017-01-26 2022-04-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンジルオキシピリジルシクロプロパンカルボン酸、その医薬組成物及び使用
EP3580222B1 (en) 2017-02-08 2021-04-07 Boehringer Ingelheim International GmbH Indanylaminoazadihydrobenzofuranylacetic acids, pharmaceutical compositions for the treatment of diabetes

Similar Documents

Publication Publication Date Title
JP2020514315A5 (enExample)
JP2020506205A5 (enExample)
JP2020505393A5 (enExample)
JP2020505400A5 (enExample)
JP2020505394A5 (enExample)
JP2019535792A5 (enExample)
JP2018526405A5 (enExample)
JP2018526352A5 (enExample)
RU2403258C2 (ru) Тиазолилдигидроиндазолы
JP2019532110A5 (enExample)
JP2017508789A5 (enExample)
JP2018522879A5 (enExample)
JP2004506736A5 (enExample)
JP2019509276A5 (enExample)
JP2009532453A5 (enExample)
JP2012513416A5 (enExample)
JP2017503760A5 (enExample)
JP2015504091A5 (enExample)
RU2016143333A (ru) Амидные производные и их фармацевтически приемлемые соли, способ их получения и медицинское применение
JP2013544268A5 (enExample)
JP2014501766A5 (enExample)
JP2016506958A5 (enExample)
IL274229B1 (en) Antibacterial compounds
JP2016534084A5 (enExample)
JP2014502988A5 (enExample)